By Jaime Llinares Taboada

 

Shares in RUA Life Sciences PLC rose Tuesday after it said that order intake for U.S. supply has returned to pre-coronavirus levels and that its vascular grafts business remains on track for FDA approval in the first quarter of 2022.

The medical-devices group said indications from its major U.S. supply customer suggest it is anticipating high-single-digit volume growth over the coming year, and opportunities are being considered regarding expanding the range of products supplied by RUA.

As for its vascular grafts division, the company said that it has already solved the contamination issues identified in previous testing. "The plan remains to have the scale up equipment fully validated during the second quarter of 2022 thus allowing us to meet growing demand for the grafts," RUA said.

Shares at 0810 GMT were up 10% at 140 pence.

 

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

 

(END) Dow Jones Newswires

August 31, 2021 04:33 ET (08:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Dic 2021 a Ene 2022 Haga Click aquí para más Gráficas Rua Life Sciences.
Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Ene 2021 a Ene 2022 Haga Click aquí para más Gráficas Rua Life Sciences.